Our reporter Xie Lan trainee reporter Li Rushi

　　On the evening of October 24, Watson Bio released its third quarterly report for 2022. The company achieved revenue of 3.706 billion yuan in the first three quarters, a year-on-year increase of 74.06%; net profit attributable to the parent was 531 million yuan, a year-on-year increase of 45.84%.

The sales volume of Watson Bio's 13-valent pneumonia conjugate vaccine and the newly added bivalent HPV vaccine increased, resulting in an increase in operating income compared with the same period of the previous year.

　　Previously, Wantai Bio also gave a dazzling transcript. In the first three quarters, its revenue was 8.651 billion yuan, a year-on-year increase of 140.56%; the net profit attributable to the parent was 3.944 billion yuan, a year-on-year increase of 231.91%.

Wantai Bio said that in the first three quarters, the company's bivalent HPV vaccine continued to maintain a boom in production and sales, and its revenue and profit grew rapidly.

　　In recent years, the domestic HPV vaccine market has grown rapidly. The approved HPV vaccines include bivalent, quadrivalent and nine-valent HPV vaccines.

In terms of bivalent HPV vaccine, Wantai Bio and Watson Bio have successfully developed this vaccine, becoming the "pioneer" of domestic HPV vaccines.

　　According to data from the China Institute for Food and Drug Control, in the first three quarters of this year, Wantai Bio-bivalent HPV vaccine has been issued in more than 200 batches, which has exceeded the number of batches issued in the whole year of last year; Watson Bio-bivalent HPV vaccine has been issued since May this year. After the official launch, 16 batches of 2,088,511 doses were approved and issued, and the volume accelerated in the third quarter.

The domestic bivalent HPV vaccine continued to increase in volume, which promoted the performance of the two vaccine listed companies to improve.

　　Benefiting from local policy support, the volume of domestic HPV vaccines is accelerating.

At present, many regions have provided free bivalent HPV vaccine to women aged 9 to 14 years.

Wantai Bio has actively participated in the pilot projects of Huimin projects in Guangdong Province, Jinan City, Shandong Province, and Chengdu City, Sichuan Province; Watson Bio's bivalent HPV vaccine was also included in the HPV vaccine Huimin implemented in Chengdu in September this year Project seedlings.

Essence Securities said that with the gradual implementation of HPV vaccine benefit policies in various places, vaccine companies are expected to continue to benefit from the increase in the penetration rate of bivalent HPV vaccines.

　　Deng Zhidong, general manager of Hainan Boao Medical Technology Co., Ltd., told the "Securities Daily" reporter: "The domestic HPV vaccine has multiple advantages, in general, it is high quality and low price. First of all, the safety and effectiveness of the domestic HPV vaccine have been verified, and the regional Second, the production capacity and supply of domestic vaccine companies are gradually expanding, which also supports the continuous increase of domestic HPV vaccines; at the same time, compared with imported vaccines, domestic vaccines are more affordable."

　　In order to gradually realize the localization of vaccines, it is also necessary for vaccine research and development enterprises to strengthen their own scientific and technological innovation capabilities.

In the first three quarters of this year, Watson Bio's research and development expenses were 677 million yuan, a year-on-year increase of 101.94%.

In recent years, the research and development expenses of vaccine research and development companies such as Watson Bio and Wantai Bio have shown an increasing trend. The domestic vaccine industry is constantly updating research and development technology and improving the research and development system.

　　Huang Zhen, vice chairman of Watson Bio, said: "The company must give full play to its own advantages, make good use of existing resources, and more actively march towards science and innovation, and take the express train of state support for scientific and technological innovation with the attitude of starting again. , to create more excellent products.” (Securities Daily)